Dun & Bradstreet (DNB)
(Real Time Quote from BATS)
$11.55 USD
+0.11 (0.96%)
Updated Sep 19, 2024 01:27 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Price, Consensus and EPS Surprise
DNB 11.55 +0.11(0.96%)
Will DNB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DNB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNB
Moody's (MCO) Trades Near 52-Week High: Time to Buy the Stock?
Dun & Bradstreet (DNB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
DNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dun & Bradstreet (DNB) Q2 Earnings Meet Estimates
Why Dun & Bradstreet (DNB) is a Top Value Stock for the Long-Term
Why Dun & Bradstreet (DNB) is a Top Value Stock for the Long-Term
Other News for DNB
Dun & Bradstreet price target raised by $1 at Barclays, here's why
Dun & Bradstreet Holdings Inc (DNB) Trading Down 3.6% on Sep 11
Ex-Dividend Reminder: Dun & Bradstreet Holdings, Old Dominion Freight Line and Southwest Airlines
Strategy To YieldBoost Dun & Bradstreet Holdings To 16.2% Using Options
Definitive Healthcare: Poor Near-Term Outlook, But New CEO May Change Things